detected the expansion of an unusual T-cell subpopulation expressing lower CD4 or CD8 levels (CD4'". CD8'") than classic T cells (CDlh', CD8h'). This subpopulation also expressed low levels of the CD3ITCRaIfi complex and was CDlS-CD13-CDl4-. A phenotypic analysis probing the activation level of CD4". CD8'9 CD4h', and CD8h' cells showed that they comprised increased counts of HLA-DR+, CDllb+, CD45RO' . and CD45RA+ cells. Subset expansion ranged from 2.1-to 13.6-fold. Statistical analysis showed that the size of some of these subsets was correlated to intrinsic features -CELL CHRONIC lymphocytic leukemia (B-CLL) is a lymphoproliferative disease characterized by clonal expansion of CD5+ B cells that accumulate in bone marrow and peripheral lymphoid tissues. It is associated with secondary immunodeficiency and an enhanced risk of infection. In vitro studies have shown that peripheral blood (PB) T cells from B-CLL patients respond poorly to mitogens and display defective helper a~tivity,"~ whereas suppressor activities may be either increased: or de~reased.'.~ Moreover, the total T-cell number is increased, CD4 to CD8 and CD45RA to CD45RO ratios are decreased, and activation markers, such as HLA-DR, CD25, and CDllb, are highly expre~sed.4~~"~ It has been suggested that this T-cell disregulation plays a role in the hypogammaglobulinemia and increased incidence of autoimmunity in B-CLL. Patients with advanced forms have higher counts of HLA-DR+ T cells and lower counts of both CD45RA' and CD8'CDI lb+ T cells than those with initial disease, and this T-cell pattern may be directly induced by the antitumor immune response.'" Studies on another B-cell lymphoproliferative disease, multiple myeloma, are in line with this view. These patients have high counts of activated CD4+ and CD8+ cells in PB and bone marrow, and expansion of activated CD8' cells corre-0 1994 by The American Society of Hematology.
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2198 of the tumor. First, CD4I0HLA-DR+ cell counts were higher in patients with stage A than those with stages 0 and C disease. Second, CD8IoHLA-DR+ cell counts were higher in patients in stable remission than in those at diagnosis. Third, CD4IoHLA-DR+. CD4'"CD45RO+, CD4'"CD45RA+, and CD4h%Dllb+ cell counts were higher in patients whose tumor cells expressed high levels of surface immunoglobulin (slg) than in those expressing low levels. The involvement of CD4'" and CD8'" cells in most of these correlations suggests that they may be tumor-reactive cells. Similar cells described in human and murine autoimmune disease have been shown to be autoreactive anergic cells, which may derive from nonclassic pathways of T-cell development. lates with disease progression.''"3 Moreover, these cells are oligoclonal, express antiidiotipic determinants specific for the autologous M protein, and display antiplasma cell cytotoxic activity.", 14 The aim of this work was to analyze the relationship between T-cell expansion and tumor cells in B-CLL. Our approach was twofold: first, to map the expansion of distinct T-cell subsets; second, to see whether their size was correlated to the clinical and biological features of the disease. We found that T-cell expansion strikingly involves cells expressing low CD4 or CD8 levels. These cells also express activation markers and their expansion correlates with the clinical status and neoplastic cell phenotype.
MATERIALS AND METHODS

Patients.
Fifty-six patients with B-CLL, observed as outpatients over a 6-month period, were studied. Mean age was 62.6 years (range, 39.8 to 88.2). Diagnosis was based on a PB expansion of cells expressing the phenotype surface immunoglobulin (sIg)'CD5+CD19+ (>5 X IO9 cells/L), and bone marrow lymphoid infiltration greater than 30%. Moreover, these cells appeared to be monoclonal according to the expression of the Ig K and A light chains as evalued by two-color direct immunofluorescence (IF), using the anti-K/anti-k Simultest (Becton Dickinson, Mountain View, CA). Patients were staged according to the method reported by Binet et a]": 42 were stage A, IO stage B, and four stage C. Blood samples were taken at a median of 43 months from diagnosis (range, 1 to 186 months). Twenty-eight patients (26 stage A, two stage B) were analyzed at diagnosis or shortly after, and had never received either chemotherapy or radiotherapy. Twenty-three (1 1 stage A, eight stage B, four stage C) were on treatment with alkylating agents (chlorambucil or cyclophosphamide), with or without prednisone. Five patients (all stage A) were off therapy in stable remission" after treatment with chlorambucil. Stable remission was defined as a partial remission (ie, a decrease of PE lymphocyte counts and palpable disease >50%, hemoglobin > 11 g/dL, and platelet count > 1 0 0 X 109/L) lasting for at least 6 months from discontinuation of chemotherapy. Forty age-matched healthy blood donors were used as normal controls.
B-CLLs were classified as CD13', CD14+, CD33'. CD25+, or CD38' when more than 30% of the tumor cells were stained by were chosen to obtain numerically comparable patient groups. It is noteworthy that the staining level displayed by sIghi and CD38' cells was always lower than 1,000 and 100 AFU, respectively, which were lower levels than those expressed by other chronic leukemias, namely lymphoma leukemias or hairy-cell leukemias. The following groups of patients were compared:
and CD33-(n = 31) versus CD33' (n = 9). Incomplete phenotyping resulted in some totals being less than 56. The phenotype was stable when eight patients were analyzed more than once.
IF assays. The following mAbs were used: Leu-2 (CDS), Leu-3 (CD4). Leu-4 (CD3). Leu-l5 (CDllb), Leu-M7 (CD13), Leu-M3 (CD14). Leu-M9 (CD33). T C h I P (Becton Dickinson); 2H4 (CD45RA), My7 (CD13), My4 (CD14), My9 (CD33) (Coulter Clone, Luton, UK); UCHLl (CD45RO). Dako-CD5, Dako-CD19, Dako-CD1 l b (Dako Immunoglobulins, Copenhagen, Denmark); 6-TCR (T-cell Science, Cambridge, MA); OKT4 (CD4), OKTS (CD8) (ATCC, Rockville, MD). PB mononuclear cells (PBMC) were prepared by gradient centrifugation (Lymphoprep, Nycomed, Oslo, Norway) of venous blood and stained by direct IF. Lymphocyte staining was analyzed with a cytofluorimeter (FACScan, Becton Dickinson) using a gate set on small nongranular cells. Staining was performed in the presence of protein A-purified mouse Ig (100 pg/mL) to saturate Fc receptors. When the distribution of CD4' and CD8+ cell subsets was investigated by two-color IF, a gate was set on positive cells, 5,000 cells were acquired, and the expression of HLA-DR. CD1 lb, CD45RA, and CD45RO was then analyzed on cells expressing low and high levels of CD4 and CD8. The staining pattern of CD4' and CD8' cells is shown in Fig 1 . Cells in the main bright staining peak were considered as high cells, whereas cells comprised between the negative control marker and this peak were considered low cells. CD4 and CD8 expression by high cells was relatively uniform and gave rise to a sharp monomodal staining peak. By contrast, low cell staining was heterogeneous, since these cells expressed different amounts of the coreceptors. The MRFI cut-off levels for high and low cells were always the same for a given staining protocol. When three-color IF was performed, CD4' or CD8' cells were stained with biotin-conjugated OKT4 and OKT8 mAb and RED613-conjugated avidin (Becton Dickinson). The expression of two of these markers was detected with the corresponding phycoerythrin (PE)-or fluorescein isothiocyanate (FITC)-conjugated mAb. Absolute cell counts were calculated by multiplying the percent size of each subset by the total lymphocyte count provided by an automatic blood-cell counter.
Statistical analysis. Differences between means were calculated with Student's t test and the nonparametric Mann-Whitney test when two groups were compared. One-and two-way analysis of variance (ANOVA) was used when three groups were compared. Computa- 
RESULTS
Recent studies have defined a new T-cell population that either does not express CD4 or CD8 or expresses lower amounts than classic CD4h' and CD8h' Since CD4' and CD8+ cell counts are increased in B-CLL, we investigated the distribution of high and low cells in these subpopulations. We found that CD4" and CD8'" cell counts were increased by 5.9-and 3.9-fold, respectively, whereas CD4h' and CD8h' cells were less strikingly expanded (2.6-and 2.8-fold) ( Table 1 ). The staining pattern of CD4+ and CD8' cells is shown in Fig 1 ( see Materials and Methods). To rule out the possibility that these data were artifactual due to contaminant monocytes or neoplastic B cells, we analyzed the expression of B-(CD19), T-(CD3, TCRaIP, TCRdS), and monocyte (CD13, CD14) cell markers in the low and high CD4' and CD8' cells by two-color IF. Table 2 and Fig 2 show that these subpopulations comprise very few B cells and monocytes: more than 95% CD4'", CD4h', and CD8h' cells and more than 90% CD8'" cells displayed the CD3'/TCRa/P+ phenotype; CD8'" cells also comprised a substantial proportion (7% 2 7%) of TCRy/S' cells. It is noteworthy that CD4'" and CD8'" cells consistently expressed lower CD3 and TCRaIP levels than their high counterparts (Fig 2) . Student's f test for paired samples showed that the differences between the CD3 and TCRaIP MRFI values in the high and low subpopulations were statistically significant ( P .05, n = 5; data not shown). T-cell expansion in B-CLL is associated with increased expression of HLA-DR, CDllb, and CD45R0, and decreased expression of CD45RA.4.'' Since HLA-DR, CD1 lb, and CD45RO are regarded as activation markers, we investigated whether they detect the same cells. Three-color staining of PBMC from six patients showed that the overlap between HLA-DR and CD1 l b expression was minimal (Fig  3) . HLA-DR' cells comprised variable proportions of CD45RA+ and CD45RO' cells, whereas CD1 Ib' cells were mostly CD45RA+ (Fig 3) . Expression of CD45RA and CD45RO was also mutually exclusive, as expected, and these subsets comprised variable numbers of CD1 lb' and HLA-DR' cells (data not shown). These data, therefore, showed that CD45RA, CD45R0, HLA-DR, and CD1 Ib detect CD4'", CD4h', CD8'", and CD8h' subsets that only partially overlap, and prompted us to investigate their distribution in a larger number of patients (Table 3 ). This analysis showed that all these subsets were expanded in patients at diagnosis (CLLD). Treated patients (CLLT) displayed a similar T-cell pattern, except for CD4h'CD45RAf, CD8hiCD45RA+, CD8'"CD45RA+, CD8h'CD1 Ib+, and CD8'"CDI lb' cells, whose counts were lower in CLLT than CLLD patients. It is noteworthy that subset expansion ranged from 2. I -to 13.6-fold, and therefore was not homogeneous.
These data show that chemotherapy affects T-cell expansion only weakly and its effect is mostly negative and only significant on a few subsets. Moreover, they suggest that the main force driving the T-cell expansion is the tumor cell itself.
To define the role played by the tumor better, we looked for correlations between the T-cell pattern and two clinical parameters that provide evidence of tumor burden and malignancy, and that may influence the antitumor immune response. The first parameter was clinical stage, which can be regarded as an index of tumor burden. We compared T-cell counts of patients with low (stage A) and high (stage B or C) tumor burden. Only treated patients were included in this analysis, since all stage C patients were treated. Stage A patients had more CD4loHLA-DR+ cells than stage B and C patients (Table 4) , whereas the other counts were similar in the two groups. The second parameter was stable remission, which corresponds to reduced tumor burden and malignancy. Patients in stable remission (CLLR) had higher counts of CD8'"HLA-DR' cells than CLLD (Table 4) . Finally, the relationship between an intrinsic feature of neoplastic cells, namely their phenotype, and the T-cell pattern was assessed. Patients were grouped according to their expression of sIg, CD5, CD13, CD14, CD33, CD25, and CD38 (see Methods). These markers were chosen because they (1) are heterogenously expressed by B-CLL cells, as found in the course of routine diagnostic analysis, (2) recognize molecules that may speculatively play a role in modulating T-cell response (see Discussion), and (3) identify groups of patients large enough to allow statistical analysis. This analysis showed that high sIg levels are associated with higher CD4IoHLA-DR', CD4l0CD45RA', CD4'"CD45RO', and CD4h'CD1 lb' cell counts (Table 4) , whereas no difference was found between the other groups.
DISCUSSION
This work analyzes T-cell subset distribution in PB of B-CLL patients, and its correlation with disease status. We Table 2 . Phenotypic Analysis of CD4'". CD8'". CDC', and CD8"' Cells 
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found that T-cell expansion involves several subsets differentially affected by disease progression and neoplastic cell phenotype. The main finding was that B-CLL patients display high counts of CD4I0 and CD8'" cells, whose expansion was proportionally higher than that of classic CD4h' and CD8hi cells. Since T-cell expansion requires T-cell activation, we analyzed the expression by low and high cells of CD45R0, CD45RA, CD1 lb, and HLA-DR, which discriminate the T-cell activation stages. CD45RO and CD45RA dis- dant in reactive lymph nodes, and their function is not 1 I-, 5 , 7-, and 9-fold in CD4'", CD8'", CD4'" CD8h' cells, known."." Moreover, CD1 1 b is expressed by activated and respectively. It is noteworthy that T-cell expansion involved memory cells in virally infected mice.'' HLA-DR was choboth CD45RO' and CD4SRA' cells in patients at diagnosis, sen because it is a well-defined activation marker. Distinct but mostly CD4SRO' cells in treated patients. These data are heterogeneously expanded T-cell subsets were found in our in line with studies reporting low proportions ofCD45RA' T B-CLL patients. The expansion of HLA-DR+ cells was the cells in B-CLL patients4."' and show that chemotherapy plays most striking, since they were increased by approximately a role in this unbalancement. Chemotherapy also affected CD4'"HLA-DR' CD8'CDl lb+ cell expansion, suggesting a greater susceptibility of these cells to chemotherapy toxicity. The difference between CLLD and CLLT was not due to the heterogeneous stage distribution, since (1) these subsets were not differently expanded in patients grouped by clinical stage, and (2) similar difference was found when the comparison was confined to stage A patients (data not shown).
A search for links between T-cell expansion and the clinical and biological features of B-CLL showed that the expansion consistently involved CD4'" and CD8'" cells. CD4I0HLA-DR+ cell counts were higher in stage A patients than in patients with advanced disease (stages B and C). This was not due to differences in the impact of chemotherapy, since (1) all of these patients were treated, (2) CD4'"HLA-DR' cell counts were not significantly different in treated and untreated patients, and (3) no difference was found between patients receiving alkylating agents as opposed to alkylating agents plus prednisone or showing different responses to chemotherapy (data not shown). These data suggest that high tumor masses have a negative influence on 2203 CD4'"HLA-DR+ cells, which may be due to real inhibition of these cell's expansion or to their trapping in the lymphoid tissues. A negative effect of high tumor masses is also suggested by the finding that stable remission was associated with increased CD8'"HLA-DR+ cell counts.
Correlations were also sought between T-cell expansion and B-CLL phenotype, using markers that are heterogeneously expressed by B-CLL patients and could speculatively play a role in T-cell recognition of the tumor. CD1434 and CD3335 are monocyte cell markers and may have a role in cell-to-cell interactions. A similar role may be possessed by CD38,36 which is expressed by activated T and B cells, whereas CD1337 is expressed by cells of the myelomonocytic lineage, corresponds to the aminopepitase N, and probably modulates the function of inflammatory peptides. CD25 is the IL-2R a chain, and its expression on B-CLL might affect T-cell activation by consuming IL-2. Last, we considered the expression level of sIg, which may function as a tumorspecific antigen. We found that the expression of high levels of sIg by neoplastic cells was associated with higher CD4I0HLA-DR+, CD4'"CD45RO+, and CD4l0CD45RA+ cell counts. In this case, CD4hiCD1 lb+ cells were also expanded. Comparison of patients expressing low and high levels of CD5 was used as a control for this analysis and no difference was found. It is noteworthy that sIg expression was the only phenotypic feature of the neoplastic cell that significantly affected the T-cell pattern. This is in line with data obtained on multiple myeloma, which suggest that T-cell activation is partly sustained by an immune response against idiotypic determinants of the M protein. " This work, therefore, indicates that CD4'" and CD8'" cells are an important component of the T-cell expansion displayed by B-CLL patients. They are not a general feature of lymphoproliferative disease, since they are not expanded in multiple myeloma patients (P. Omedk, personal observation). They resemble the double-negative (DN) T cells, which are expanded in human and murine autoimmune diseases, and either do not express CD4 or CD8 or express low Low counts of these cells are normally present in PB, but DellaBona et a1 reported that oligoclonal TCRd p' DN cells are expanded in a minority of healthy individuals.I8 Other investigators, working on murine models, suggested that these cells may be specific for self-antigens, and may either derive from an extrathymic pathway of T-cell development22,2' or belong to an unique thymus-derived Tcell lineage, not dependent on positive and negative selection.'8 Moreover, von Boehmer et a12' reported that if T cells obtained from female mice transgenic for a TCRaIP specific for the male antigen HY are transferred into male nude mice, expressing the correct genetic background, the HY-specific cells rapidly expand, but, after a few days, downmodulate the CD3/TCR and CD8 molecules and become unresponsive to stimulation via the CD3/TCR. It is noteworthy that CD4'" and CD8"' cells from B-CLL patients display a downmodulation of CD4, CD8, and CD3/TCR that is quantitatively similar to that described by these investigators, suggesting that these cells, too, may be anergic. This may account for the weak mitogenic response of T cells from B-CLL patients to stimuli acting via the CD3/TCR (personal observation).
Porcelli et a1 showed that some human TCRaIP' DN clones recognize antigens presented by CD 1, a major histocompatability complex class I-like molecule expressed in association with P2-microglobulin.39~40 This is noteworthy, since it has been reported that subsets of normal CDS+ and CDY cells express CDlc, and that B-CLL cells may express CDla and/or CDIC.~"~' Further studies are needed to define the specificity of CD4'" and CD8'" cells and to assess their relation with CD1 expression by B-CLL cells. However, this work suggests that they may be tumor-specific cells that proliferate in vivo in response to tumor antigens, but have poor effector functions. Cells of this kind are easy to detect and purify, and could be a good system for studying antitumor immunity and a useful tool in immunotherapy.
